Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Nobody else seems concerned AT ALL

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Dec 23, 2021 5:11pm

124 Views

Post# 34259402

RE:RE:RE:Nobody else seems concerned AT ALL

Golden Arm, think you may owe an apology for your accusations that were unfounded.

GoldenArm wrote: Agree. Volume low so any selling is going to bring prce down. There is no interest in selling. We already had the day when lots of shares were dumped.

Riverfolk pumped this stock hard and now has disappeared. I could be wrong about River but I don't think I am. Riverfolk et al holdings would have been liquidated as soon as news came out. After that River went silent so I'm pretty sure Riverfolk moved on to another Alias and is pumping another stock.

However you can't deny the truth about this stock. It is poised to win big once the 325 people study is done.